	US 12,268,729 B2
	Therapeutic agent for neurodegenerative disease
Toru Miyazaki, Tokyo (JP)
Appl. No. 17/280,157
Filed by Toru Miyazaki, Tokyo (JP)
PCT Filed Sep. 30, 2019, PCT No. PCT/JP2019/038530 § 371(c)(1), (2) Date Mar. 25, 2021, PCT Pub. No. WO2020/071318, PCT Pub. Date Apr. 9, 2020.
Claims priority of application No. 2018-186759 (JP), filed on Oct. 1, 2018.
Prior Publication US 2022/0000975 A1, Jan. 6, 2022
Int. Cl. A61K 38/17 (2006.01); A61K 35/76 (2015.01); A61K 35/761 (2015.01); A61K 48/00 (2006.01); A61P 25/28 (2006.01)

CPC A61K 38/1761 (2013.01) [A61K 35/76 (2013.01); A61K 35/761 (2013.01); A61P 25/28 (2018.01); A61K 48/00 (2013.01)]

10 Claims

1. A method for treating a neurodegenerative disease, comprising administering Apoptosis Inhibitor of Macrophage (AIM) or a nucleic acid encoding the AIM to a subject with a neurodegenerative disease,

wherein the AIM is a human-derived AIM protein having the amino acid sequence of SEQ ID NO: 1, and

wherein the neurodegenerative disease is a disease caused by amyloid plaque in the brain,

whereby the neurodegenerative disease is treated in the subject.